Apatinib is Apatinib Mesylate Tablets, gastric cancer can be treated with this product, which needs to be used under doctor’s instruction. Apatinib mesylate tablets can inhibit tumor angiogenesis, and can be used in patients with advanced gastroesophageal adenocarcinoma and gastric adenocarcinoma that have progressed or relapsed after receiving 2 kinds of systemic chemotherapy. The visible adverse reactions of Apatinib Mesylate Tablets include granulocytopenia, leukopenia, thrombocytopenia, hypertension, proteinuria, malaise, hand-foot syndrome, hoarseness, upper gastrointestinal bleeding, cardiotoxicity, hepatotoxicity. The drug is contraindicated in people who are allergic to any of the components of the product, have active bleeding and ulcers, intestinal obstruction, intestinal perforation, within 30 days after a major operation, class III-IV cardiac insufficiency, hypertension uncontrollable by medication, severe hepatic and renal insufficiency. The drug should be used under the guidance of a doctor, do not blindly use and stop the drug, any discomfort during the use of the drug is recommended to consult a doctor in a timely manner in order to avoid delays in the condition.